Off-Label Use of Letermovir as Preemptive Anti-Cytomegalovirus Therapy in a Pediatric Allogeneic Peripheral Blood Stem Cell Transplant.
GCV-resistant CMV
intolerance to FOS
off-label letermovir use
pediatric allogeneic peripheral blood stem cell transplant
Journal
Infection and drug resistance
ISSN: 1178-6973
Titre abrégé: Infect Drug Resist
Pays: New Zealand
ID NLM: 101550216
Informations de publication
Date de publication:
2021
2021
Historique:
received:
12
12
2020
accepted:
19
02
2021
entrez:
1
4
2021
pubmed:
2
4
2021
medline:
2
4
2021
Statut:
epublish
Résumé
Despite the effectiveness of the currently available antiviral drugs in treating cytomegalovirus (CMV) infection, high rates of adverse effects are associated with their use. Moreover, a problem of increasing importance is the emergence of drug-resistant CMV infection. Here, we describe the first case of off-label use of letermovir (LMV) as preemptive antiviral therapy, in a pediatric allogeneic peripheral blood stem cell transplant recipient with ganciclovir-resistant CMV infection who was intolerant to foscarnet and unable to achieve viral clearance after seven doses of cidofovir. After the administration of LMV, a gradual reduction in viral load was observed and within 6 weeks of LMV treatment, after more than 6 months of positive CMV-DNAemia, the patient cleared the infection. No adverse effects associated with LMV were observed during treatment. In this pediatric study case, the off-label use of LMV for the treatment of CMV infection has been well tolerated and proved to be effective in leading to the suppression of viral replication.
Identifiants
pubmed: 33790588
doi: 10.2147/IDR.S296927
pii: 296927
pmc: PMC8001039
doi:
Types de publication
Case Reports
Langues
eng
Pagination
1185-1190Informations de copyright
© 2021 Chiereghin et al.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest for this work.
Références
Antimicrob Agents Chemother. 2019 Feb 26;63(3):
pubmed: 30642941
Bone Marrow Transplant. 2007 Jul;40(1):55-61
pubmed: 17468776
J Pediatric Infect Dis Soc. 2020 Sep 17;9(4):486-489
pubmed: 31362308
Curr Hematol Malig Rep. 2020 Apr;15(2):90-102
pubmed: 31981100
Antiviral Res. 2019 Jan;161:116-124
pubmed: 30472161
Clin Infect Dis. 2020 Apr 10;70(8):1525-1533
pubmed: 31179485
Lancet Infect Dis. 2019 Aug;19(8):e260-e272
pubmed: 31153807
Am J Transplant. 2018 Dec;18(12):3060-3064
pubmed: 30286286
Biol Blood Marrow Transplant. 2010 Sep;16(9):1309-14
pubmed: 20353832
World J Clin Cases. 2015 Dec 16;3(12):973-9
pubmed: 26677445
Front Microbiol. 2019 May 28;10:1186
pubmed: 31191499
N Engl J Med. 2017 Dec 21;377(25):2433-2444
pubmed: 29211658
Biol Blood Marrow Transplant. 2020 May;26(5):978-984
pubmed: 32035273
Am J Transplant. 2011 May;11(5):1079-84
pubmed: 21521474
Haematologica. 2016 Jul;101(7):803-11
pubmed: 27365460
Transplantation. 2020 Feb;104(2):404-409
pubmed: 32000236
Comput Struct Biotechnol J. 2015 Feb 10;13:153-9
pubmed: 25750703
Clin Infect Dis. 2019 Apr 8;68(8):1420-1426
pubmed: 30137245
Transpl Infect Dis. 2019 Dec;21(6):e13187
pubmed: 31585500
Am J Transplant. 2021 Apr;21(4):1622-1628
pubmed: 33320429
Biol Blood Marrow Transplant. 2014 Dec;20(12):1958-67
pubmed: 25139217
Mediterr J Hematol Infect Dis. 2019 Jan 01;11(1):e2019001
pubmed: 30671207
Rev Med Virol. 2016 May;26(3):161-82
pubmed: 26990717
J Clin Microbiol. 2018 Mar 26;56(4):
pubmed: 29305542
Clin Microbiol Rev. 2010 Oct;23(4):689-712
pubmed: 20930070
Infect Drug Resist. 2019 Jun 04;12:1481-1491
pubmed: 31239725
J Antimicrob Chemother. 2009 Mar;63(3):600-8
pubmed: 19147520
Eur J Case Rep Intern Med. 2020 Apr 20;7(7):001622
pubmed: 32665929
Am J Transplant. 2020 Jun;20(6):1703-1711
pubmed: 31883426
Transpl Immunol. 2016 Feb;34:60-4
pubmed: 26687013
Med Microbiol Immunol. 2019 Dec;208(6):825-834
pubmed: 31289930